Profile
E.
Michael Egan has been Vice Chairman of TransMolecular, Inc. since April 2009 and is Senior Vice President of Commercial Development for GenVec, Inc. He was President and Chief Executive Officer of TransMolecular, Inc. Prior to joining TransMolecular in July 2005, he was Chief Operating Officer of Diacrin, Inc., a Director of Repligen Clinical Partners LP and Secretary and Treasurer of Repligen Sandoz Research Corp.
Mr. Egan was a Laboratory Supervisor of Dana-Farber Cancer Institute, Inc. He has over 15 years of experience in business development and laboratory management.
Mr. Egan received a BS degree in Biology from Boston College and an MA degree and a Certificate of Special Studies in Administration and Management from Harvard University.
Former positions of E. Michael Egan
Companies | Position | End |
---|---|---|
TransMolecular, Inc.
TransMolecular, Inc. BiotechnologyHealth Technology TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs. | President | 2009-04-09 |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Repligen Clinical Partners LP
Repligen Clinical Partners LP Pharmaceuticals: OtherHealth Technology Part of Repligen Corp., Repligen Clinical Partners LP is an American company formed to fund the further development of Repligen Corporation's recombinant platelet factor-4 protein. | Director/Board Member | - |
Diacrin, Inc. (Delaware)
Diacrin, Inc. (Delaware) Medical SpecialtiesHealth Technology Diacrin, Inc. develops human cell transplant therapeutic products. The company is headquartered in Wilmington, DE. | Chief Operating Officer | - |
GENVEC INC | Corporate Officer/Principal | - |
Training of E. Michael Egan
Boston College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 5 |
---|---|
GenVec, Inc.
GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
TransMolecular, Inc.
TransMolecular, Inc. BiotechnologyHealth Technology TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs. | Health Technology |
Diacrin, Inc. (Delaware)
Diacrin, Inc. (Delaware) Medical SpecialtiesHealth Technology Diacrin, Inc. develops human cell transplant therapeutic products. The company is headquartered in Wilmington, DE. | Health Technology |
Repligen Clinical Partners LP
Repligen Clinical Partners LP Pharmaceuticals: OtherHealth Technology Part of Repligen Corp., Repligen Clinical Partners LP is an American company formed to fund the further development of Repligen Corporation's recombinant platelet factor-4 protein. | Health Technology |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Health Services |
- Stock Market
- Insiders
- E. Michael Egan